How GPCR-targeting therapies are advancing the fight against inflammatory disease
Drug Target Review
JUNE 16, 2025
DT-9046 is currently progressing through pre-IND studies, supported by a robust data package, including head-to-head benchmarks and strong patent protection. DT-9046 is currently progressing through pre-IND studies, supported by a robust data package, including head-to-head benchmarks and strong patent protection.
59 
Let's personalize your content